Research Analysts Offer Predictions for ASP Isotopes Inc.'s FY2024 Earnings (NASDAQ:ASPI)

ASP Isotopes Inc. (NASDAQ:ASPI - Free Report) - Research analysts at HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for shares of ASP Isotopes in a research report issued on Wednesday, April 17th. HC Wainwright analyst H. Ihle now forecasts that the company will earn ($0.11) per share for the year, down from their prior forecast of $0.07. HC Wainwright currently has a "Buy" rating and a $5.50 price objective on the stock. The consensus estimate for ASP Isotopes' current full-year earnings is $0.07 per share.

ASP Isotopes Trading Up 0.3 %

Shares of ASP Isotopes stock traded up $0.01 during trading hours on Friday, reaching $3.10. 519,444 shares of the company's stock were exchanged, compared to its average volume of 594,865. ASP Isotopes has a 52-week low of $0.28 and a 52-week high of $4.97. The firm has a market capitalization of $151.65 million, a price-to-earnings ratio of -6.33 and a beta of 5.03. The company has a fifty day moving average of $3.67 and a 200-day moving average of $2.40. The company has a current ratio of 1.85, a quick ratio of 1.85 and a debt-to-equity ratio of 0.01.

Insider Buying and Selling

In other news, Director Robert John Andrew Ryan bought 15,596 shares of the business's stock in a transaction that occurred on Monday, January 29th. The shares were acquired at an average cost of $2.35 per share, with a total value of $36,650.60. Following the transaction, the director now owns 537,055 shares of the company's stock, valued at approximately $1,262,079.25. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 26.30% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Armistice Capital LLC purchased a new position in shares of ASP Isotopes in the 1st quarter worth $2,702,000. Renaissance Technologies LLC acquired a new stake in ASP Isotopes in the 2nd quarter valued at $272,000. GSA Capital Partners LLP acquired a new stake in ASP Isotopes in the 4th quarter valued at $608,000. Vanguard Group Inc. increased its holdings in ASP Isotopes by 761.7% in the 4th quarter. Vanguard Group Inc. now owns 176,314 shares of the company's stock valued at $316,000 after purchasing an additional 155,853 shares in the last quarter. Finally, Rathbones Group PLC acquired a new stake in ASP Isotopes in the 4th quarter valued at $272,000. 16.80% of the stock is owned by hedge funds and other institutional investors.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.